CDC and fungal diseases : why are fungal diseases a public health issue? by National Center for Emerging and Zoonotic Infectious Diseases (U.S.). Division of Foodborne, Waterborne, and Environmental Diseases.
CS257980
National Center for Emerging and Zoonotic Infectious Diseases
Division of Foodborne, Waterborne, and Environmental Diseases
CDC and Fungal Diseases:
Why are fungal diseases a public health issue?
Fungal diseases pose an important threat to public health for several reasons. 
 • Opportunistic infections such as cryptococcosis and aspergillosis are becoming 
increasingly problematic as the number of people with weakened immune systems 
rises. This group includes cancer patients, transplant recipients, other people taking 
medications that weaken the immune system, and people with HIV/AIDS. 
 • Hospital-associated infections such as candidemia are a leading cause of bloodstream 
infections in the United States. Advancements and changes in healthcare practices can 
provide opportunities for new and drug-resistant fungi to emerge in hospital settings. 
 • Community-acquired infections such as coccidioidomycosis (Valley fever), 
blastomycosis, and histoplasmosis, are caused by fungi that live in the environment 
in specific geographic areas. These fungi are sensitive to changes in temperature and 
moisture, and we don’t know how long-term climate change may be affecting their 
growth and distribution.
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The shaded areas, where certain disease-causing fungi are suspected to 
live in the United States, are approximate and deserve further study.
What is CDC doing to 
combat fungal diseases?
We are taking action to prevent and control fungal diseases through a 
variety of domestic and international activities:
 • Responding to outbreaks with epidemiologic investigations
 • Monitoring long-term trends in fungal diseases through surveillance
 • Developing, evaluating, and promoting cost-effective prevention 
guidelines and intervention strategies 
 • Detecting and identifying fungal pathogens in human and 
environmental samples 
 • Assisting laboratories in developing countries to perform 
diagnostic tests
Current challenges and 
future directions:
 • Defining the public health burden of fungal 
diseases
 • Developing improved methods for earlier diagnosis 
 • Understanding the geographic distribution of 
environmental fungal diseases
 • Determining the effects of climate conditions on 
environmental disease-causing fungi
 • Identifying groups of people at highest risk to help 
focus prevention strategies
 • Providing education to healthcare providers and 
raising awareness among the public about the 
threat of fungal diseases
Endemic Fungal Diseases in the United States
Preventing deaths from cryptococcal meningitis
CDC is working with several countries 
on strategies to prevent deaths due to 
cryptococcal meningitis.
Coccidioides lives in dry, dusty soil. It was 
recently found in south-central Washington.
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In people with weakened immune systems, the fungus Cryptococcus neoformans causes 
life-threatening meningitis in hundreds of thousands of people every year. Cryptococcus 
is the most common cause of meningitis in sub-Saharan Africa, and is a leading cause of 
death among people with HIV. A simple, affordable blood test for cryptococcal antigen 
can detect cryptococcal infection before meningitis develops, creating opportunities to 
prevent this deadly disease.  CDC is helping implement targeted cryptococcal screening 
programs and build laboratory capacity to detect these infections early. This allows for 
more timely treatment, reduced mortality, and overall improved quality of life.
Monitoring Candida bloodstream infections 
with multi-state surveillance
Candida is a common cause of hospital-associated bloodstream infections in the United States. CDC has 
identified improved adherence to infection prevention guidelines and improved national surveil-
lance as two important healthcare-associated infection prevention “Winnable Battle” goals.  CDC 
conducts population-based, active laboratory surveillance in several U.S. locations to monitor 
the epidemiology of candidemia and trends in antifungal drug resistance among different 
Candida species. Surveillance indicates that candidemia is a particular problem in infants 
and the elderly and that resistance to some antifungal medications is an emerging public 
health issue. Results from the ongoing surveillance allow CDC to identify areas to focus 
candidemia prevention and intervention strategies.
 
Disease detectives respond 
to new fungal threats
Responding to outbreaks and emerging threats is 
a core part of CDC’s work on fungal diseases. Valley 
fever sickens thousands of people every year when 
they inhale the microscopic fungus Coccidioides. 
Until recently, scientists believed that Coccidioides 
only lived in soil in the Southwestern United States 
and parts of Latin America. The fungus was 
discovered in south-central Washington after 
several residents developed Valley fever. Samples from 
one patient and soil from the suspected exposure site 
were identical by whole genome sequencing, proving that 
the infection was acquired in Washington. CDC is developing 
new tools that make it faster and easier to detect Coccidioides 
in the environment. Those tools will help scientists determine 
where a person was most likely infected, how strains are related, 
and which areas could pose a risk – information that is essential for 
raising awareness about the disease among other public health officials, 
healthcare providers, and the public.
